Radiopeptide Combination Improves Survival in Metastatic Neuroendocrine Cancers

Share this content:

(ChemotherapyAdvisor) – Patients with metastasized neuroendocrine cancers had improved efficacy and overall survival following repeated cycles of two of the most commonly used radioisotopes in somatostatin-based radiopeptide therapy, investigators reported in the Journal of Clinical Oncology published online March 5.

The radioisotope 90yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([90YDOTA]-TOC) was administered alone (n=237) and in combination with 177lutetium-labeled DOTA-TOC ([177Lu-DOTA]-TOC) (n=249) for three or more treatment cycles to patients with neuroendocrine cancers.

Those receiving [90YDOTA]-TOC plus [177Lu-DOTA]-TOC had significantly longer survival than patients receiving [90Y-DOTA]-TOC alone (5.51 vs. 3.96 years; HR, 0.64; P=0.006). Rates of severe hematologic toxicities (6.3% vs. 4.4%) and severe renal toxicity (8.9% vs. 11.2%) were comparable in both groups.

“Contrary to the current practice of using single-isotope radiopeptide therapy, our results suggest expanding the therapeutic options by using a combination of radioisotopes,” the investigators wrote, adding that a randomized trial is warranted to confirm these results.

Novel radiopeptides are being developed for use in various malignancies.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs